In patients with diabetes, SGLT2-inhibition appeared to be well-tolerated in terms of electrocardiographic changes by showing no significant difference in the duration of PR interval, QT interval and QRS width as well as no relevant changes in ST-T segments compared to non-SGLT2-i users16, however data on potential beneficial effect of SGLT2-Inhibition in patients suffering from MI expressed by ECG changes are missing. The gene discussed is SLC5A2; the disease is diabetes mellitus.